Daiichi Sankyo Launches Prasugrel In UK
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo launched April 8 antiplatelet agent Efient (prasugrel) in the UK. The launch is the first for prasugrel in the world. Daiichi obtained European approval in February. Jointly developed with Ube Industrials, Daiichi Sankyo is collaborating with Eli Lilly to develop and market the drug in the U.S. and Europe. The two plan to launch prasugrel to German and French markets shortly. (Click here for more - Japanese language